Multi-resistant pathogens cause increases in healthcare costs due to the demand for more expensive drugs and prolonged hospital stays. Multi-resistant drugs are responsible for increased morbidity and mortality of patients admitted to hospitals. These hospital-acquired infections affect the most fragile patients in intensive care units; oncology and neonatology, which often result in high mortality.

The Infection Prevention and Control (IPC) Technical and Clinical Hub team provides technical leadership and coordination of the IPC work at WHO headquarters, including through the IPC Taskforce. It also coordinates the work on sepsis. The IPC Hub is located within the Integrated Health Services (IHS) department in the Universal Health Coverage and Life Course division and works jointly with the IPC team in the WHO’s Health Emergencies (WHE) division and the AMR division. The IPC Hub team, along with the IPC WHE team, co-leads the IPC pillar of the WHO response to the COVID-19 pandemic.

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *